ARC HBR – High Bleeding Risk evaluator

Cerc is very proud to announce the launch of a new app designed to help identify High Bleeding Risk patients :


The ARC-HBR application is modelled on a consensus definition of High Bleeding Risk (HBR) for patients who are candidates for treatment with a coronary stent. Very easy to use, the evaluator helps physicians at the bedside to quickly identify HBR patients.

Click on the picture below to discover this highly valued new tool.

The full text of the ARC-HBR definition has been published in the European Heart Journal and Circulation.

To learn more, watch the video below about « High-bleeding risk patients: Guidelines and recommendations from the ARC HBR initiative ».


May 2019

A very interesting article published in JACC Cardiovascular Intervention about our VIVA trial:

> Read the very positive editorial from Danny Dvir and Vinnie Bapat

> Read the hole paper & get more information about VIVA


EuroPCR 2019

May 2019

We are proud to announce that trials managed by CERC will be presented during EuroPCR’s sessions

The ARC initiative managed by CERC: the ARC HBR definitions will be presented on Wednesday, 22nd May.

To know more, click here

EuroPCR 2019

May 2019

Be sure you won’t miss the opportunity to discover how CERC can support your research activities and enhance your trial visibility

Come and visit us at Booth M6, Level 2

To know more, click here


EuroPCR 2018

May 2018






CERC’s 10 year anniversary

May 2018


CERC was founded in 2008 by a group of interventional cardiologists who firmly believed in the need for establishing a new CRO dedicated to Cardiology to enhance the quality and increase the numbers of clinical studies initiated in Europe. Our self-assigned mission, supported by our industrial and pharmaceutical partners, was to design groundbreaking clinical studies with the purpose of redefining medical practice in order to improve our patients’ outcomes.

The international, multicultural team that we have been gradually building at CERC is composed of high level scientists from various backgrounds (15 languages are currently spoken at CERC) who have enabled us to become a highly reputable clinical research organization.

We are very proud to have achieved our initial objective of successfully carrying out clinical trials with the invaluable involvement of physicians and medical device companies.

We have been instrumental in helping many centers to undertake clinical research studies for the first time and we have guided them throughout their journey to becoming very efficient investigating centers. Other renowned cardiologists have joined CERC’s founding group and their experience and expertise have enriched CERC’s strategies.

CERC has already conducted numerous major studies and is currently coordinating many more.

We are extremely grateful to all our sponsors for the trust they have placed in us, to the physicians who have contacted us with innovative ideas for original studies, to the investigators and study coordinators who have been tirelessly enrolling patients, to our teams in CERC, CERC Asia and CERC Deutschland who strive  daily to bring these studies to fruition, to the CEC and DSMB members who have offered their knowledge and their thoroughness, and finally, to the CERC’s founders who relentlessly contribute to enhancing clinical research achievements and improving patient care, thus allowing us to envision  a promising future.






May 2018


BioFreedom STEMI Registry in Asia

I am most excited to partner CERC Asia to get the Biofreedom STEMI registry. STEMI FREE would provide a great opportunity to investigate the STEMI population in Asia in a scientifically robust manner. The use of Biofreedom stent in Primary Angioplasty should be the logical next step to explore the unique Biolimus property in ACS patients and how the polymer free stent perform in “unknown bleeding risk” ACS subjects.

Paul Ong, Principal investigator of the BiofFreedom Stemi Free Registry

I am looking forward to working closely with like minded investigators across Asia to run the study. The chance to make new friends and explore budding trial sites will be equally rewarding.

I am very grateful  for placing the trust in me. I am confident that with the expertise and support from CERC Asia we can deliver a well conducted study with robust clinical data.

This is the beginning of a beautiful partnership in Asia.



CERC@ARC HBR Meeting Washington 2018

13th April 2018


CERC was proud to organize the first ARC HBR meeting in Washington’s American College of Cardiology last Friday 13th of April 2018.



CERC@TCT Denver 2017

30th October to 2nd November 2017


CERC will be present at TCT Denver, Colorado, feel free to come visit us at Booth (number to be confirmed)

Presentation of results : Late Breaking Trial at TCT 2017 (Colorado Convention Center, Denver, Colorado)

Session : Main Arena III, Wednesday, Nov 1.

Title: SENIOR: A Randomized Trial of a Bioresorbable Polymer-Based Metallic DES vs a BMS with Short DAPT in Patients With Coronary Artery Disease Older than 75 Years

Date: Wednesday, November 1st, 2017

Time: 11:00:00 AM – 11:12:00 AM




1st November 2017


Primary Endpoint results at TCT 2017 by Prof Olivier Varenne and simultaneous publication in Lancet.

Presentation of results : Late Breaking Trial at TCT 2017 (Colorado Convention Center, Denver, Colorado)Session : Main Arena III,

Title: SENIOR: A Randomized Trial of a Bioresorbable Polymer-Based Metallic DES vs a BMS with Short DAPT in Patients With Coronary Artery Disease Older than 75 Years

Date: Wednesday, November 1st, 2017 | 11:00:00 AM – 11:12:00 AM



CERC@AICT Melbourne

23th to 26th November 2017


CERC Asia will be present at AICT Melbourne, feel free to come visit us at Booth #9




3rd to 5th December 2017


CERC will be present at ICI Tel Aviv, feel free to come visit us at Booth (number to be confirmed)




CERC@ESC Barcelona

26th to 30th August 2017


Marie-Claure Morice will be present at ESC Congress Barcelona 2017 will do the following lecture :

At 14:00 ESC Andreas Grüntzig Lecture on Interventional Cardiology
The revolution in the treatment of patients with aortic stenosis.




16th to 19th May 2017


We are proud to present several studies during the PCR, stay tuned and follow us on Twitter (@CERC_CRO)

Detailed program on the website of PCR.





CERC at EuroPCR 2017

16th-19th May 2017


CERC will be present at EuroPCR 2017 in Paris (Palais des Congrès), which will take place from 16th to 19th of May 2017.

We are delighted to welcome you at booth M6 (Level 2) !

To take an appointment, please contact : Isabelle SIMOES







20th April 2017



Prof Garot from Massy Hospital has enrolled the first patient in the SCOPE II (Safety and efficacy Comparison Of two TAVI in an Prospective randomized Evaluation II: A randomized controlled non-inferiority trial evaluating early safety and clinical efficacy of the Symetis ACURATE NEo compared to the Medtronic Evolut R bioprosthesis in transfemoral transcatheter aortic valve implantation.) study.





14th April 2017



Dr Gillian Jessurun from Treant Zorggroep, Scheper Hospital has enrolled the first patient in the investigator initiated MASTER DAPT (MAnagement of patients post bioresorbable polymer STEnt implantation with an abbreviated DAPT regimen) study, effectively launching the ambitious global investigation.





CERC@PCR Tokyo Valves

7th to 9th April 2017


Marie-Claure Morice was present during the PCR Tokyo Valve as Course Director.

CERC at HighTech 2017

1-3 février 2017

CERC sera présent au prochain congrès HighTech à Marseille, du 1er au 3 février 2017.

Venez nous rencontrer au stand 18 !



CERC at AsiaPCR Innovators Day

January 18, 2017


CERC Asia, our recently founded Singapore-based subsidiary, will be introduced at the Innovators day during AsiaPCR, which takes place on 18th January 2017.

Come and discuss with us important topics in clinical research and new technologies in the cardiovascular therapeutic area.



CERC at AsiaPCR 2017

19-21 January 2017

CERC will be present at AsiaPCR 2017 in Singapore, which will take place from 19th to 21st of January 2017.

We are delighted to welcome you at booth 19!!



CERC at TCT 2016

October 29-November 2, 2016

We are proud to announce that the results of Leaders free and Oppose trials, sponsored respectively by Biosensors and Occlutech, and which were managed by CERC will be presented during this year’s TCT congress:

LEADERS FREE : Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk. Presented by Dr Philip Urban on Sunday , Oct 30. 12:45 PM. Main Arena


LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial . Presented by Pr Didier Carriée on Monday, Oct 31. 1:15 PM. Room 143A


OPPOSE: Occlutech Percutaneous PFO Closure: Safety and Efficacy Registry. Presented by David Hildick-Smith on Monday , Oct 31. 12:45 PM. Room 144B


Person to be contacted during the congress:

Marie-Claude MORICE



CERC and BePatient are happy to announce the lounge of UP SMART FOLLOW UP, a company dedicated to connected follow up of patients in clinical trials. Contact person: Thomas RENOU



CERC is happy to announce that CERC Asia is now open.

Clinical research has no frontiers and is rapidly expanding in Asia in parallel with the growing number of patients undergoing treatment. As CERC is involved in several ongoing trials conducted in Asian sites, we decided to set up CERC ASIA in Singapore in order to coordinate the trials directly from this strategic region and support Asian research whenever necessary.

 Contact person : Rosa D’ALESSIO

      CERC at  ICI Meeting 2016
4-6 December, 2016    
    ICI Meeting 2016 – the premier International Conference for Innovations in Cardiovascular Systems (Heart, Brain and Peripheral Vessels) and High-Tech Life Science Industry will be taking place on December 4-6 2016 in Tel Aviv, Israel.  

      CERC at  PCR London Valves 2016
18-20 September, 2016  
  CERC will be present at London Valves PCR 2016 from 18th to 20th September 2016. Come and visit us at booth 24!!

    CERC at  Asia PCR 2016
21st-23rd January, 2016
CERC will attend the Asia PCR in Singapore, January 21-23 Come and visit us at booth 31

  ICI Meeting 2015
13th-15th December, 2015  
The ICI Meeting is the premier International Conference for Innovations in cardiovascular systems (Heart Brain and Peripheral Vessels) and High-Tech Life Science Industry. ICI 2015 banner_20year_celebration
    CERC at  TCT 2015
11th-15th October, 2015
  CERC at TCT 2015 CERC will attend the TCT 2015 in San Francisco, October 11-15

  CERC is proud to announce the presentation by Philip Urban in the Late breaking trial session in the Main Arena of the LeadersFree trial. LEADERS FREE : A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding TCT2015-banner-mobile
CERC at  PCR London Valves
20th-22nd September, 2015
CERC will be present at London Valves PCR 2015 from 20th to 22nd September 2015. Come and VISIT US!! Back to Home page